PMA device
Revo MRI Surescan Ipg and Pacing System
Medtronic, Inc. · Implantable Pulse Generator, Pacemaker (Non-Crt) (LWP, Class III) · First FDA decision Feb 8, 2011, newest Apr 23, 2020Bradycardia and heart block
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
15
PMA pathway
Device trials
4
Naming "Revo"
MAUDE reports
1,113
Brand "Revo", since 2015
PubMed studies
233
Mentioning "Revo"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Revo MRI Surescan Ipg and Pacing System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 15 decisions filed under this name.
- REVO MRI SURESCAN IPG AND PACING SYSTEMPMA supplement
P090013-S301 · Decided Apr 23, 2020 · 297 days after receipt · Normal 180 Day Track
Device type: Implantable pulse generator, pacemaker (non-CRT) (LWP) · Cardiology
- Revo MRI SureScan IPGPMA supplement
P090013-S288 · Decided Oct 3, 2018 · 97 days after receipt · Normal 180 Day Track No User Fee
Device type: Implantable pulse generator, pacemaker (non-CRT) (LWP) · Cardiology
- Revo MRI SureScan and CapSureFix MRI SureScan LeadPMA supplement
P090013-S281 · Decided Jun 28, 2018 · 76 days after receipt · Normal 180 Day Track
Device type: Implantable pulse generator, pacemaker (non-CRT) (LWP) · Cardiology
3 more FDA decisions with a free account
Older decisions: P090013-S220, P090013-S165, P090013-S149, P090013-S112, P090013-S107, P090013-S085, P090013-S063, P090013-S047, P090013
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Revo", any status and sponsor, newest update first.
- The ReVo Study: Low-volume vs High-volume Rectal IrrigationPivotal-lookingCompleted
Guy's and St Thomas' NHS Foundation TrustAcademic, hospital or other
NCT06100055 · 180 participants · Start May 10, 2024 · Primary completion Jun 30, 2026
Device: Rectal Irrigation · For: Constipation - Functional; Constipation; Constipation by Outlet Obstruction and 1 more
Sites: London, United Kingdom
Otto Bock Healthcare Products GmbHNot on our public-company list
NCT04239222 · 27 participants · Start Mar 10, 2020 · Primary completion Mar 11, 2022
Device: Revo-M; Taleo and 1 more · For: Lower Limb Amputation Below Knee (Injury); Lower Limb Amputation Above Knee (Injury); Lower Limb Amputation Knee
Sites: Mesa, Arizona; Linthicum, Maryland; Dayton, Ohio · 4 sites in all
- Articulated Laparoscopic Instruments Clinical StudyStatus unknown
Yonsei UniversityAcademic, hospital or other
NCT05550974 · 1,155 participants (planned) · Start Sep 2022 · Primary completion Oct 2024
Device: Minimally Invasive Surgery · For: Gastric Cancer
Sites: Seoul, South Korea
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Revo", and for the whole product code for context.
This brand
1,113 reports: 389 malfunction, 710 injury, 13 death
Whole product code LWP
142,226 reports: 58,138 malfunction, 82,585 injury, 1,486 death
Newest reports for this brand
- Revo MRI SureScanMalfunction
3004209178-2026-16683 · Received Oct 1, 2026 · Event dated Sep 9, 2026
Device type: Implantable Pulse Generator, Pacemaker (Non-Crt) (LWP)
Device problem as coded: Failure to Interrogate
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Revo MRI SureScanInjury
MEDTRONIC PUERTO RICO OPERATIONS CO.
3004209178-2026-15178 · Received Sep 9, 2026 · Event dated Aug 14, 2026
Device type: Implantable Pulse Generator, Pacemaker (Non-Crt) (LWP)
Device problem as coded: Reset Problem; Data Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Revo MRI SureScanMalfunction
3004209178-2026-13439 · Received Aug 11, 2026 · Event dated Mar 1, 2026
Device type: Implantable Pulse Generator, Pacemaker (Non-Crt) (LWP)
Device problem as coded: Appropriate Device Problem Term/Code Not Available
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Revo"[tiab]. The summary above synthesizes these.
- Revo-i assisted robotic central pancreatectomy.
Ku G, Kang I, Lee WJ, et al. · Ann Hepatobiliary Pancreat Surg · 2020Case Reports
- Cholecystectomy using the Revo-i robotic surgical system from Korea: the first clinical study.
Lim JH, Lee WJ, Choi SH, et al. · Updates Surg · 2021Clinical Trial, Phase II
- The Revo-i Robotic Surgical System in Advanced Pancreatic Surgery: A Second Non-Randomized Clinical Trial and Comparative Analysis to the da Vinciࡊ System.
Kim JS, Choi M, Hwang HS, et al. · Yonsei Med J · 2024Clinical Trial, Comparative Study
- Future Platforms of Robotic Surgery.
Alip SL, Kim J, Rha KH, et al. · Urol Clin North Am · 2022Historical Article, Review
- Comparing Revo-i and da Vinci in Retzius-Sparing Robot-Assisted Radical Prostatectomy: A Preliminary Propensity Score Analysis of Outcomes.
Alip S, Koukourikis P, Han WK, et al. · J Endourol · 2022
- Disagreement of Radial Peripapillary Capillary Density Among Four Optical Coherence Tomography Angiography Devices.
Sawaspadungkij M, Apinyawasisuk S, Suwan Y, et al. · Transl Vis Sci Technol · 2023Research Support, Non-U.S. Gov't
- Robotic cholecystectomy using Revo-i Model MSR-5000, the newly developed Korean robotic surgical system: a preclinical study.
Lim JH, Lee WJ, Park DW, et al. · Surg Endosc · 2017
- REVO: Resampling of ensembles by variation optimization.
Donyapour N, Roussey NM, Dickson A · J Chem Phys · 2019
- Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).
Wang P, Chen Y, Wang F, et al. · Nat Commun · 2025Clinical Trial, Phase II, Randomized Controlled Trial
- Rare-earth orthovanadate nanoparticles trigger Ca2+-dependent eryptosis.
Yefimova S, Onishchenko A, Klochkov V, et al. · Nanotechnology · 2023
- Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience.
Pereira-Souza AL, Ambrósio R, Bandeira F, et al. · J Refract Surg · 2022Case Reports
- First experience of pancreaticoduodenectomy using Revo-i in a patient with insulinoma.
Kang I, Hwang HK, Lee WJ, et al. · Ann Hepatobiliary Pancreat Surg · 2020Case Reports
Other devices of this type
Also filed under product code LWP.
- CapSureFix MRI LeadMedtronic, Inc. · PMA 2025
- Assurity MRI / Endurity MRI PacemakersAbbott Medical · PMA 2026
- Imageready MR Conditional Pacing System and Ingevity Pace/Sense LeadBoston Scientific · PMA 2026
- INGEVITY MRI tined and extendable/retractable fixation leads / INGEVITY+ leadsBoston Scientific · PMA 2026
- Tendril MRI Pacing Leads / Assurity MRIAbbott Medical · PMA 2025
- Percepta Quad CRT-P MRI SureScanMedtronic, Inc. · PMA 2019
- AdvantioBoston Scientific Corp · PMA 2018
- Acuity Spiral LeadBoston Scientific Corp · PMA 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.